- Home
- UTHR vs ACM Comparison
UTHR vs ACM Comparison
Compare UTHR & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- ACM
- Stock Information
- Founded
- UTHR 1996
- ACM 1980
- Country
- UTHR United States
- ACM United States
- Employees
- UTHR N/A
- ACM N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- UTHR Health Care
- ACM Consumer Discretionary
- Exchange
- UTHR Nasdaq
- ACM Nasdaq
- Market Cap
- UTHR 14.4B
- ACM 12.6B
- IPO Year
- UTHR 1999
- ACM 2007
- Fundamental
- Price
- UTHR $308.00
- ACM $104.36
- Analyst Decision
- UTHR Buy
- ACM Strong Buy
- Analyst Count
- UTHR 12
- ACM 9
- Target Price
- UTHR $392.00
- ACM $118.33
- AVG Volume (30 Days)
- UTHR 439.7K
- ACM 978.7K
- Earning Date
- UTHR 04-30-2025
- ACM 05-05-2025
- Dividend Yield
- UTHR N/A
- ACM 1.00%
- EPS Growth
- UTHR 18.86
- ACM N/A
- EPS
- UTHR 25.10
- ACM 4.58
- Revenue
- UTHR $2,994,100,000.00
- ACM $16,047,510,000.00
- Revenue This Year
- UTHR $11.45
- ACM $6.63
- Revenue Next Year
- UTHR $6.11
- ACM $5.34
- P/E Ratio
- UTHR $12.27
- ACM $22.79
- Revenue Growth
- UTHR 19.84
- ACM 4.55
- 52 Week Low
- UTHR $260.41
- ACM $82.23
- 52 Week High
- UTHR $417.82
- ACM $118.56
- Technical
- Relative Strength Index (RSI)
- UTHR 57.25
- ACM 68.32
- Support Level
- UTHR $290.02
- ACM $101.13
- Resistance Level
- UTHR $319.40
- ACM $105.75
- Average True Range (ATR)
- UTHR 10.02
- ACM 2.38
- MACD
- UTHR 2.72
- ACM 0.88
- Stochastic Oscillator
- UTHR 69.99
- ACM 90.49
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.